After Novartis pact, macrocycle shop Unnatural Products gets $45M Series B
Unnatural Products Series B financing secures $45M after a Novartis pact to advance macrocycle drugs toward the clinic....
16 March, 2026
News
Vico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1
Vico Therapeutics begins twice-annual dosing of VO659 in HD, SCA3 & SCA1 patients. FDA IND cleared. First ASO targeting CAG repeat expansion across polyglutamine diseases....
24 February, 2026
Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Study
“The preclinical progress of ALE1 and ALE2 underscores the company’s potential to deliver much-needed treatment options, and we are excited to support the continued advancement of these programs in 2025 and beyond.”...
01 December, 2025
Hillstar Bio Launches with $67 Million Series A Financing to Develop Next Wave of Precision Immunotherapies to Transform Autoimmune Treatment
“The preclinical progress of ALE1 and ALE2 underscores the company’s potential to deliver much-needed treatment options, and we are excited to support the continued advancement of these programs in 2025 and beyond.”...
25 March, 2025
Alesta Therapeutics Raises €65 Million Series A Financing to Advance Oral Small Molecules for Rare Diseases
“The preclinical progress of ALE1 and ALE2 underscores the company’s potential to deliver much-needed treatment options, and we are excited to support the continued advancement of these programs in 2025 and beyond.”...
08 January, 2025
Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor
The FDA's IND clearance is a pivotal moment for Accent Therapeutics, propelling our lead program into the clinical arena. ATX-559 has shown remarkable promise in preclinical studies, and we're excited to now evaluate its potential to meaningfully improve outcomes for patients facing these challenging malignancies....
24 October, 2024
Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO
Judo Bio has discovered a novel approach to create oligonucleotide medicines targeted to the kidney, an organ that has been challenging to access for genetic medicines. The company has completed preclinical studies successfully demonstrating receptor-mediated delivery of oligonucleotides to the kidney with proprietary ligand-siRNA conjugates...
07 October, 2024
Eli Lilly licenses preclinical antisense program designed to treat ALS, dementia
Eli Lilly added another neuroscience program to its pipeline, licensing an antisense oligonucleotide from the ALS biotech QurAlis. The deal, announced Monday, is the latest indicator that Lilly is still investing in new neuro drugs ahead of the FDA advisory committee for its Alzheimer’s drug donanemab...
03 June, 2024
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
"We are delighted to announce the backing of an exceptional investor syndicate who share our commitment to advancing innovative therapies for patients with cancer," said Shakti Narayan, PhD, JD, CEO of Accent Therapeutics. "These additional resources position us well to file INDs this year for...
23 January, 2024
Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. Phase Ib trial for sovilnesib, Volastra’s second KIF18A inhibitor, is anticipated to open in Q1 2024....
30 October, 2023